NFE2L2 and chronic kidney disease: The aim of this study was to determine whether dimethyl fumarate, through its effect on the Nrf2 pathway, might result in a decreased incidence of T2D, CVD and CKD, in patients with MS, using real-world data derived from US administrative claims databases.